Soleus Capital Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001802630

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q4 2025 · 95 positions · Total reported value $2.71B · Top-10 concentration 51.5% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 72.6% · 27 new · 36 cut · 27 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -6.9% · vs SPY -9.0% · Prev Value $2.90B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.4% · vs SPY -3.6% · Latest Value $2.81B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q4 2025 13F filing, Soleus Capital Management, L.P. disclosed 95 equity positions with a combined reported value of $2.71B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 51.5% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2025 were XBI ($353.60M), KRYS ($232.01M), CELC ($180.36M). By sector, the heaviest allocations are Health Care 81.7%, Other 18.3%. Versus the prior quarter, allocation shifted toward Other (+2.6pp) and away from Health Care (-2.6pp).

Versus the prior quarter, Soleus Capital Management, L.P. opened 27 new positions, trimmed 36 and fully exited 27, a turnover rate of 72.6% of positions. The portfolio's overlap with the prior quarter was 52% of names.

The largest new positions opened in Q4 2025 were DXCM ($86.09M), PODD ($42.64M), ALKS ($37.00M).

Of the 27 positions fully exited versus the prior quarter, the largest were ELV ($83.90M), GRFS ($24.90M), IART ($20.65M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2025)

  • DXCM DEXCOM INC · $86.09M
  • PODD INSULET CORP · $42.64M
  • ALKS ALKERMES PLC · $37.00M
  • LIVN LIVANOVA PLC · $34.92M
  • IMVT IMMUNOVANT INC · $28.22M
  • PCVX VAXCYTE INC · $28.10M
  • TFX TELEFLEX INCORPORATED · $23.19M
  • EWTX EDGEWISE THERAPEUTICS INC · $22.58M

Fully Exited (vs previous quarter)

  • ELV ELEVANCE HEALTH INC FORMERLY · prev qtr: $83.90M
  • GRFS GRIFOLS S A · prev qtr: $24.90M
  • IART INTEGRA LIFESCIENCES HLDGS C · prev qtr: $20.65M
  • QURE UNIQURE NV · prev qtr: $11.67M
  • ADMA ADMA BIOLOGICS INC · prev qtr: $10.82M
  • VSTM VERASTEM INC · prev qtr: $8.26M
  • NUVL NUVALENT INC · prev qtr: $7.61M
  • ESTA ESTABLISHMENT LABS HLDGS INC · prev qtr: $5.72M

Insider Transactions (Form 4)

Latest Soleus Capital Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-11 Conversion Parabilis Medicines, Inc. 527,070 $9.48 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 125,000 $20.00 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 375,000 $20.00 SEC filing

All insider transactions →

Fund Profile

Soleus Capital Management, L.P. is an SEC-registered 13F filer based in Greenwich, CT, United States. As of Q3 2026 it reported 97 US equity positions with a combined value of $2.81B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: GREENWICH, CT, United States
  • SEC registration: 801-118942 (status: Approved), registered 2020-06-25
  • Regulatory AUM (Form ADV): $3.66B as of 2026-04-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 12 private funds, of which 1 hedge funds

Portfolio Structure

  • 97 positions · $2.81B reported value (Q3 2026)
  • Top 10 holdings = 53.0% of reported value
  • Largest position: KRYS (KRYSTAL BIOTECH INC) at 13.5%
  • Average position size: $29.00M

Sector Tilt

  • Health Care 98.6%
  • Information Technology 0.0%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q3 2026: 27 new, 28 added, 36 reduced, 27 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 81.7%
Other 18.3%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 2.90M $353.60M 13.04%
13.04%
Add
2 941.06K $232.01M 8.56%
8.56%
Reduce
3 1.81M $180.36M 6.65%
6.65%
Add
4 8.53M $110.30M 4.07%
4.07%
Reduce
5 362.97K $106.98M 3.95%
3.95%
Reduce
6 3.14M $93.58M 3.45%
3.45%
Reduce
7 1.30M $86.09M 3.18%
3.18%
New
8 1.32M $78.45M 2.89%
2.89%
Add
9 887.00K $77.44M 2.86%
2.86%
Add
10 2.53M $77.23M 2.85%
2.85%
Reduce
11 5.21M $74.15M 2.73%
2.73%
Add
12 1.86M $59.06M 2.18%
2.18%
Hold
13 9.99M $51.73M 1.91%
1.91%
Reduce
14 2.25M $47.21M 1.74%
1.74%
Add
15 573.61K $45.31M 1.67%
1.67%
Add
16 150.00K $42.64M 1.57%
1.57%
New
17 2.70M $41.74M 1.54%
1.54%
Reduce
18 1.21M $39.50M 1.46%
1.46%
Reduce
19 486.24K $38.38M 1.42%
1.42%
Add
20 1.32M $37.00M 1.36%
1.36%
New
21 567.50K $34.92M 1.29%
1.29%
New
22 639.00K $31.34M 1.16%
1.16%
Add
23 23.29M $30.74M 1.13%
1.13%
Add
24 60.00K $29.23M 1.08%
1.08%
Reduce
25 1.11M $28.22M 1.04%
1.04%
New
26 608.96K $28.10M 1.04%
1.04%
New
27 70.00K $27.84M 1.03%
1.03%
Add
28 299.40K $27.61M 1.02%
1.02%
Reduce
29 764.00K $27.51M 1.01%
1.01%
Add
30 31.73K $26.68M 0.98%
0.98%
Reduce
31 764.00K $25.88M 0.95%
0.95%
Add
32 175.98K $24.96M 0.92%
0.92%
Add
33 587.00K $24.21M 0.89%
0.89%
Add
34 7.31M $24.05M 0.89%
0.89%
Hold
35 190.00K $23.19M 0.85%
0.85%
New
36 1.22M $23.13M 0.85%
0.85%
Reduce
37 910.00K $22.58M 0.83%
0.83%
New
38 10.88M $22.29M 0.82%
0.82%
Add
39 702.05K $19.48M 0.72%
0.72%
Add
40 7.71M $19.04M 0.70%
0.70%
New
41 646.39K $18.65M 0.69%
0.69%
New
42 92.50K $18.38M 0.68%
0.68%
New
43 711.98K $16.97M 0.63%
0.63%
New
44 1.02M $15.79M 0.58%
0.58%
New
45 408.90K $12.90M 0.48%
0.48%
Add
46 300.03K $12.85M 0.47%
0.47%
Reduce
47 796.74K $12.29M 0.45%
0.45%
Hold
48 900.00K $11.27M 0.42%
0.42%
Add
49 268.50K $11.05M 0.41%
0.41%
Reduce
50 383.37K $10.69M 0.39%
0.39%
Add

FAQ

What did Soleus Capital Management, L.P. buy in 2025-Q4?

In its 2025-Q4 13F filing, Soleus Capital Management, L.P. reported 95 equity positions worth $2.71B in aggregate; its largest disclosed positions were XBI ($353.60M), KRYS ($232.01M), CELC ($180.36M).

How large is Soleus Capital Management, L.P.'s portfolio?

Soleus Capital Management, L.P. reported $2.71B of long equity holdings across 95 positions as of 2025-Q4. Top-10 holdings account for 51.5% of reported value.

What is Soleus Capital Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/soleus-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →